Skip to content

Earnings yield at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-2.6%-1.1pp
Arrowhead Research logo
Arrowhead ResearchARWR
-3.4%-1.3pp
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
-5.2%-1.1pp
PTC Therapeutics logo
PTC TherapeuticsPTCT
15.4%+10.2pp
Scholar Rock logo
Scholar RockSRRK
-7.2%-1.0pp
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
7.3%+0.6pp

Other financials

Income statement

See full
Operating income-$125.3M-2.4%
Net income-$120.9M-4.8%
EPS (diluted)-$0.73+30.5%

Balance sheet

See full
Cash & equivalents$753.1M+59.5%
Total debt$168.7M+623%
Total equity$865.1M+29.3%
Total assets$1.1B+49.8%

Cash flow

See full
Operating cash flow-$144.9M-36.9%
CapEx$221.0K-77.5%
Free cash flow-$145.1M-35.8%

Valuation

See full
Market cap$3.35B+153%

Returns & leverage

See full
Return on equity-58.9%-4.4pp
Debt / equity0.2×+0.2×
Current ratio19.9×-0.4×

Where this comes from

Calculated from Dyne Therapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dyne Therapeutics, Inc.'s earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dyne Therapeutics, Inc.'s earnings yield?
Dyne Therapeutics, Inc. (DYN) reported earnings yield of -15.1% in Q1 2026.
How has Dyne Therapeutics, Inc.'s earnings yield changed year-over-year?
Dyne Therapeutics, Inc.'s earnings yield increased by 51.3% year-over-year, from -31% to -15.1%.
What is the long-term trend for Dyne Therapeutics, Inc.'s earnings yield?
Over 5 years (2020 to 2025), Dyne Therapeutics, Inc.'s earnings yield has grown at a 19.4% compound annual growth rate (CAGR), from -5.7% to -13.9%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.